Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 10, 2019

SELL
$15.53 - $19.75 $1.86 Million - $2.36 Million
-119,465 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$15.58 - $28.41 $1.86 Million - $3.39 Million
119,465 New
119,465 $1.99 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $86M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.